医学
塞库金单抗
后代
免疫系统
儿科
怀孕
情感(语言学)
产科
免疫学
免疫病理学
安全概况
年轻人
临床试验
作者
Ming He,Mei Fang Zhang,Min Jia,Tao Yu,Linbo Sun,Ting Ao Tang
标识
DOI:10.1080/09546634.2025.2584945
摘要
OBJECTIVE: Generalized pustular psoriasis of pregnancy (GPPP) is a rare and serious skin disease. Although IL-17A inhibitors have shown potential for safety and efficacy during pregnancy, further evidence is needed. This study aimed to evaluate the efficacy and safety of secukinumab administered during two consecutive pregnancies, with an emphasis on long-term follow-up of the offspring. MATERIALS AND METHODS: This case report described a 21-year-old female patient who received secukinumab treatment for GPPP during two consecutive pregnancies. Clinical efficacy was assessed using the Generalized Pustular Psoriasis Area and Severity Index (GPPASI), the Generalized Pustular Psoriasis Global Assessment (GPPGA), and the Dermatology Life Quality Index (DLQI). Regular follow-up evaluations were conducted to monitor potential manifestations of psoriasis in the offspring and assess their vaccination status. RESULTS: After first - pregnancy secukiumab injection, GPPASI, GPPGA, and DLQI scores dropped rapidly; similar efficacy occurred in the second pregnancy with no adverse events. Vaccination confers no immunosuppression or infection risk in offspring. CONCLUSIONS: Secukinumab showed a favorable safety profile for both mother and infant in two consecutive pregnancies. Importantly, no immune abnormalities were noted in the offspring after receiving attenuated live vaccines, indicating that secukinumab may not affect vaccine efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI